Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
Iclusig comes too late to rescue Takeda
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
